CN101511867B - 细胞因子衍生物 - Google Patents

细胞因子衍生物 Download PDF

Info

Publication number
CN101511867B
CN101511867B CN200780032719.1A CN200780032719A CN101511867B CN 101511867 B CN101511867 B CN 101511867B CN 200780032719 A CN200780032719 A CN 200780032719A CN 101511867 B CN101511867 B CN 101511867B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
polypeptide
nucleic acid
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780032719.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN101511867A (zh
Inventor
奥利弗·哈特利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Biotechnology Switzerland SARL
Original Assignee
MINTAKA MEDICAL RES FOUNDATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MINTAKA MEDICAL RES FOUNDATION filed Critical MINTAKA MEDICAL RES FOUNDATION
Publication of CN101511867A publication Critical patent/CN101511867A/zh
Application granted granted Critical
Publication of CN101511867B publication Critical patent/CN101511867B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
CN200780032719.1A 2006-07-25 2007-07-25 细胞因子衍生物 Active CN101511867B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0614755.7 2006-07-25
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (2)

Publication Number Publication Date
CN101511867A CN101511867A (zh) 2009-08-19
CN101511867B true CN101511867B (zh) 2014-04-09

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780032719.1A Active CN101511867B (zh) 2006-07-25 2007-07-25 细胞因子衍生物

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
EP3813870B1 (en) * 2018-05-28 2023-11-15 Orion Biotechnology Switzerland Sàrl Ccr5 inhibitor for use in treating cancer
CN112469430B (zh) * 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
EP4646232A1 (en) 2023-01-06 2025-11-12 Université de Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1128538A (zh) * 1993-06-09 1996-08-07 康诺特实验室有限公司 串联的合成hiv-1肽类

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748938B1 (fr) 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1128538A (zh) * 1993-06-09 1996-08-07 康诺特实验室有限公司 串联的合成hiv-1肽类

Also Published As

Publication number Publication date
HK1131162A1 (en) 2010-01-15
MX2009000918A (es) 2009-08-26
RU2009106436A (ru) 2010-08-27
PL2076532T3 (pl) 2011-07-29
JP5224603B2 (ja) 2013-07-03
US9328153B2 (en) 2016-05-03
CN101511867A (zh) 2009-08-19
EP2076532B1 (en) 2010-12-01
RS51854B (sr) 2012-02-29
EP2076532A2 (en) 2009-07-08
BRPI0715331B1 (pt) 2021-04-13
US8686111B2 (en) 2014-04-01
SI2076532T1 (sl) 2011-06-30
CA2658806C (en) 2017-01-03
DK2076532T3 (da) 2011-03-07
WO2008012689A3 (en) 2008-05-08
ZA200901342B (en) 2010-11-24
US20090317363A1 (en) 2009-12-24
ES2361455T3 (es) 2011-06-17
HRP20110146T1 (hr) 2011-06-30
AU2007278894B2 (en) 2012-08-09
JP2009544304A (ja) 2009-12-17
RU2461567C2 (ru) 2012-09-20
BRPI0715331B8 (pt) 2021-05-25
ATE490270T1 (de) 2010-12-15
ME01320B (me) 2013-12-20
NZ575092A (en) 2011-08-26
PT2076532E (pt) 2011-03-02
AU2007278894A1 (en) 2008-01-31
KR20090060281A (ko) 2009-06-11
CY1111630T1 (el) 2015-10-07
DE602007010969D1 (de) 2011-01-13
CA2658806A1 (en) 2008-01-31
GB0614755D0 (en) 2006-09-06
BRPI0715331A2 (pt) 2013-07-16
KR101530353B1 (ko) 2015-06-26
US20130330305A1 (en) 2013-12-12
WO2008012689A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
US9328153B2 (en) Cytokine derivatives
ES2273492T3 (es) Peptidos antagonistas de il-6.
US20050220790A1 (en) Amino-terminally truncated rantes as chemokine antagonists
JP2002507388A (ja) Ｒａｎｔｅｓ変異体およびその治療用途
JP2005525089A (ja) ケモカイン・アンタゴニストとして作用するケモカイン突然変異体
Cai et al. Loss of C-terminal alpha-helix decreased SDF-1alpha-mediated signaling and chemotaxis without influencing CXCR4 internalization
HK1131162B (en) Cytokine derivatives
TW200524625A (en) Antiviral compositions which inhibit paramyxovirus infection
KR101138930B1 (ko) Ｈⅰｖ ｎｃ 단백질을 포함하는 ａⅰｄｓ 예방 및 치료용조성물
Boykins et al. Chemical synthesis and characterization of chemokine RANTES and its analogues
JP2000198798A (ja) 抗ｃｃｒ５抗体認識ペプチドミミックス、その製造方法およびその用途
CA2233367A1 (en) Short forms of chemokine .beta.-8

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20191107

Address after: geneva

Patentee after: Orion biotechnology Switzerland Co., Ltd

Address before: Prestat, Switzerland

Patentee before: Mintaka Medical Res Foundation